Teva's Synribo approved for home administration

JERUSALEM — Teva Pharmaceutical Industries on Monday announced that the Food and Drug Administration approved Synribo (omacetaxine mepesuccinate) for injection, to include home administration. With the announcement of the approval, physicians who treat adults with chronic or accelerated phase CML (who are no longer responding to or can't tolerate  two or more tyrosine kinase inhibitors) now have the option to allow patients to administer Synribo at home.



“As we continue to expand our oncology portfolio and services at Teva, the updated labeling for Synribo demonstrates our commitment to improving the overall experience and lowering barriers to treatment for people living with CML,” said Bill Campbell, VP and general manager, Teva Oncology. “Home administration can reduce the number of required doctor office visits for patients being treated with Synribo, while still maintaining close collaboration with their healthcare provider to manage their treatment regimen.”



Teva is finalizing a comprehensive specialty pharmacy support program, which will help facilitate home administration of Synribo for HCPs, their patients and caregivers. It's expected to "go live" in the second quarter of 2014.  



“As an oncology nurse practitioner who has treated CML patients for nearly 20 years, I’m thrilled to see this unique therapy become available for home administration,” said Sandra Corbin, CRNP at Calvert Hematology and Oncology. “Patients may initially express concern at the thought of self-injecting — but with training and support, most can become skilled at administering the subcutaneous injections.”